Journal
CLINICAL IMMUNOLOGY
Volume 161, Issue 2, Pages 366-372Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2015.10.002
Keywords
Primary immunodeficiency; N-acetylglucosamine-phosphate mutase hyper-IgE syndrome; Congenital defects of glycosylation; CDG
Categories
Funding
- FP7 project European Genetic Disease Diagnostics
- EURO-GENE-SCAN [Health-F5-2008-223293]
- Swedish Medical Research Council
- Stockholm County Council
- Southeastern Norway Regional Health Authorities Technology Platform for Structural Biology and Bioinformatics [2012085]
Ask authors/readers for more resources
Phosphoglucomutase 3 (PGM3) is an enzyme converting N-acetyl-glucosamine-6-phosphate to N-acetylglucosamine-l-phosphate, a precursor important for glycosylation. Mutations in the PGM3 gene have recently been identified as the cause of novel primary immunodeficiency with a hyper-IgE like syndrome. Here we report the occurrence of a homozygous mutation in the PGM3 gene in a family with immunodeficient children, described already in 1976. DNA from two of the immunodeficient siblings was sequenced and shown to encode the same homozygous missense mutation, causing a destabilized protein with reduced enzymatic capacity. Affected individuals were highly prone to infections, but lack the developmental defects in the nervous and skeletal systems, reported in other families. Moreover, normal IgE levels were found. Thus, belonging to the expanding group of congenital glycosylation defects, PGM3 deficiency is characterized by immunodeficiency, with or without increased IgE levels, and with variable forms of developmental defects affecting other organ systems. (C) 2015 The Authors. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available